Evidence map›Paper›PMID 39795134›Full record

ArticleMolecules (Basel, Switzerland)2024

Dereplication of Natural Product Antifungals via Liquid Chromatography-Tandem Mass Spectrometry and Chemical Genomics.

Nathaniel J Brittin, David J Aceti, Doug R Braun, Josephine M Anderson, Spencer S Ericksen, Scott R Rajski, Cameron R Currie, David R Andes, Tim S Bugni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nathaniel J BrittinPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0009-0004-4309-7735
David J AcetiSmall Molecule Screening Facility, UW Carbone Cancer Center, Madison, WI 53792, USA.ORCID 0000-0002-3627-6274
Doug R BraunPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI 53705, USA.
Josephine M AndersonPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI 53705, USA.
Spencer S EricksenSmall Molecule Screening Facility, UW Carbone Cancer Center, Madison, WI 53792, USA.ORCID 0000-0003-4907-1160
Scott R RajskiPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-0238-8411
Cameron R CurrieDepartment of Biochemistry and Biomedical Sciences, M.G. DeGroote Institute for Infectious Disease Research, David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, ON L8S 4L8, Canada.
David R AndesDepartment of Medical Microbiology and Immunology, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53706, USA.
Tim S BugniPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-4502-3084

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Novel antimicrobials targeting MDR pathogens from animal microbial symbiontsU19AI142720 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SAFDAR, NASIA · 2019 to 2023
$30.1M
NCI NIH HHS P30 CA014520NIAID NIH HHS U19 AI142720NIH HHS 1U19AI142720-22A1
6 · The paper itself

Abstract

Recently expanded reports of multidrug-resistant fungal infections underscore the need to develop new and more efficient methods for antifungal drug discovery. A ubiquitous problem in natural product drug discovery campaigns is the rediscovery of known compounds or their relatives; accordingly, we have integrated Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for structural dereplication and Yeast Chemical Genomics for bioprocess evaluation into a screening platform to identify such compounds early in the screening process. We identified 450 fractions inhibiting

Indexed as

Antifungal AgentsBiological ProductsGenomicsCandida albicansChromatography, LiquidDrug DiscoveryMicrobial Sensitivity TestsTandem Mass SpectrometryAntifungal AgentsBiological Productsantifungalchemical genomicsdereplicationdrug discoverydrug resistancemechanism of actionmetabolomicsnatural productsscreeningtargeted bioprocess

Identifiers

PMID39795134
PMCPMC11721837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.